Core Viewpoint - CloudTop New Horizon (01952) experienced a significant stock increase of over 8%, reaching HKD 67.1 with a trading volume of HKD 408 million, following news of product shortages and strategic investments [1] Group 1: Product Development and Regulatory Approvals - There have been reports of shortages for Budesonide enteric-coated capsules (brand name: Nafucon), prompting CloudTop New Horizon to submit a capacity expansion application to the National Medical Products Administration (NMPA) in February [1] - On August 4, CloudTop New Horizon announced that its application for capacity expansion of Nafucon, the first and only fully approved treatment for IgA nephropathy in China, has been officially approved by the NMPA [1] Group 2: Strategic Investments - On August 1, CloudTop New Horizon announced a strategic increase in its stake in I-Mab, investing USD 30.9 million, equivalent to approximately HKD 242.6 million [1] - Following this transaction, CloudTop New Horizon will hold approximately 16.1% of I-Mab's shares, making it the largest shareholder of the company [1] - The CEO of CloudTop New Horizon stated that this strategic investment in I-Mab further enhances the company's global positioning in the next-generation tumor immunotherapy pipeline [1]
港股异动 | 云顶新耀(01952)午后涨超8% 耐赋康扩产已获国家药监局批准 公司近期战略增持I-Mab股权